Editas Medicine develops therapeutics based on CRISPR–Cas9 gene editing technology. At the 2018 Benchling User Forum, Michael Dinsmore, Associate Director of Informatics at Editas Medicine, outlined how he uses the Benchling platform to automate NGS and CRISPR workflows, integrate instruments, and improve traceability. Moving to a unified platform has freed up Editas’ informatics teams to focus on innovative development projects. In this presentation Michael outlines a few such projects, including the use of Benchling’s APIs and data warehouse to create live reporting dashboards and track R&D progress.
Visit our Customer Stories page to learn more about how companies use Benchling to accelerate their biologics R&D.